S'abonner

Effectiveness of a tailored intervention to reduce antibiotics for urinary tract infections in nursing home residents: a cluster, randomised controlled trial - 28/10/21

Doi : 10.1016/S1473-3099(21)00001-3 
Sif Helene Arnold, PhD a, b, , Jette Nygaard Jensen, PhD b, Lars Bjerrum a, Volkert Siersma, PhD a, Christine Winther Bang, MSc a, Marius Brostrøm Kousgaard, PhD a, Anne Holm, PhD a
a Department of Public Health, University of Copenhagen, Copenhagen, Denmark 
b Department of Clinical Microbiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark 

* Correspondence to: Dr Sif Helene Arnold, Department of Public Health, University of Copenhagen, 1014 Copenhagen, Denmark Department of Public Health University of Copenhagen Copenhagen 1014 Denmark

Summary

Background

When suspecting a urinary tract infection (UTI), the nursing home staff contacts a physician with clinical information on behalf of the resident; hence, poor understanding of UTI or a lack of clinical communicative skills can cause overtreatment with antibiotics. We investigated whether a tailored intervention that improves knowledge about UTI and communication skills in nursing home staff influences antibiotic prescriptions for UTI.

Methods

This open-label, parallel-group, cluster randomised controlled trial was done at 22 participating nursing homes in Denmark. Patients were eligible if they were nursing home residents aged 65 years or older, had the nursing home listed as their permanent address, and resided in a living space designated for those with dementia or somatic health-care needs. We included nursing homes that were not participating in other UTI projects and those in which staff were present at all hours. Using computer-generated random numbers and stratification by municipality, a statistician randomised the nursing homes (1:1) to receive either interactive educational sessions and use of a dialogue tool or to continue standard practice. The statistical analysis was blinded. Staff attended 75 min sessions over 8 weeks to learn how to distinguish between UTIs and asymptomatic bacteriuria, evaluate non-specific symptoms, and use the dialogue tool. The primary outcome was the number of antibiotic prescriptions for acute UTI per resident per days at risk, defined as the number of days the resident had been present at the nursing home during the trial period. The trial is registered at ClinicalTrials.gov, NCT03715062.

Findings

Between June 1, 2017, and June 1, 2018, 22 of 68 invited nursing homes were recruited. Of 22 randomised nursing homes (n=1625 residents), 11 received the intervention (770 [92·2%] of 835 allocated residents) and 11 were in the control group (705 [89·2%] of 790 allocated residents). The standardised number of nursing home staff was 572 in the intervention group and 535 in the control group. All nursing homes completed the trial. 65 residents were excluded from data collection in the intervention group and 85 were excluded in the control group. 1470 residents (intervention n=765; control n=705) were analysed for the primary endpoint. The number of antibiotic prescriptions for UTI per resident was 134 per 84 035 days at risk in the intervention group and 228 per 77817 days at risk in the control group. The rate ratio (RR) of receiving an antibiotic for UTI was 0·51 (95% CI 0·37–0·71) in the unadjusted model and 0·42 (0·31–0·57) in the adjusted model. Of 140 diary entries of suspected UTIs, no deaths were reported. 421 (28·5%) of 1475 residents were admitted to hospital. The risk of all-cause hospitalisation increased in the intervention group (adjusted model RR 1·28, 95% CI 0·95–1·74), whereas all-cause mortality was lower in the intervention group (0·91, 0·62–1·33).

Interpretation

The intervention effectively reduced antibiotic prescriptions and inappropriate treatments for UTI without substantially influencing all-cause hospitalisations and mortality.

Funding

Danish Ministry of Health and the Velux Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 21 - N° 11

P. 1549-1556 - novembre 2021 Retour au numéro
Article précédent Article précédent
  • Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study
  • Catherine Hyams, Robin Marlow, Zandile Maseko, Jade King, Lana Ward, Kazminder Fox, Robyn Heath, Anabella Tuner, Zsolt Friedrich, Leigh Morrison, Gabriella Ruffino, Rupert Antico, David Adegbite, Zsuzsa Szasz-Benczur, Maria Garcia Gonzalez, Jennifer Oliver, Leon Danon, Adam Finn
| Article suivant Article suivant
  • Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort
  • Pyry N Sipilä, Nelli Heikkilä, Joni V Lindbohm, Christian Hakulinen, Jussi Vahtera, Marko Elovainio, Sakari Suominen, Ari Väänänen, Aki Koskinen, Solja T Nyberg, Jaana Pentti, Timo E Strandberg, Mika Kivimäki

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.